Keratan Sulfate, Quantitative by LC-MS/MS, Urine
Screening and monitoring of patients with suspected Morquio syndrome (MPS IV), in conjunction with other mucopolysaccharides screen tests.
New York DOH Approval Status
Morning void is preferred.
Transfer 2 mL urine to ARUP Standard Transport Tube and freeze immediately. (Min: 1 mL)
CRITICAL FROZEN. Separate specimens must be submitted with multiple tests are ordered.
Specimens containing preservatives.
Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month
Liquid Chromatography-Tandem Mass Spectrometry
|Age||Total Keratan Sulfate (ug/mg CRT)|
|0-11 months||5.65 - 20.73|
|1 year - 5 years||1.75 - 6.81|
|6 years - 15 years||0.67 - 4.16|
|16 years and older||0.29 - 0.85|
Refer to report.
Keratan Sulfate, Total is calculated as the sum of the two disaccharides, LacNAc1 and LacNAc2, per milligram of creatinine (CRT).
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2012261||LacNAc1 (S1 monosulfated), Urine|
|2012262||LacNAc2 (S2 disulfated), Urine|
|2012263||Keratan Sulfate, Total Urine|
|2012264||Keratan Sulfate, Urine Interpretation|
|3005207||EER Keratan Sulfate, Urine||11502-2|
- MPS IVa